The costs were treated deterministically, but statistical analyses were conducted to determine the influence of clinical and demographic factors on the total costs.
For the study on AF predictors, analyses were carried out on three samples corresponding to the three populations specified (see 'Study Population' section) . Power calculations, if performed, were not reported. An overall sample of 10,550 patients was enrolled between 1 January 1994 and 30 June 1999. There were 8,709 patients for the CABG sample, 1,217 patients for the valve only sample and 624 patients for the CABG and valve sample. In the CABG group, the mean age was 63 (+/-13) years for those developing AF and 55 (+/-15) years for those not developing AF. The proportions of women were 42% (AF) and 46% (no AF), respectively. For the valve only sample, the mean age was 68 (+/-9) years for those developing AF and 62 (+/-11) years for those not developing AF. The proportions of women were 27% (AF) and 26% (no AF), respectively. For the CABG and valve sample, the mean age was 71 (+/-9) years for those developing AF and 67 (+/-11) years for those not developing AF. The proportions of women were 33% (AF) and 36% (no AF), respectively.
For the study on the effect of AF on 5-year survival, a sample of 25,975 patients from 1980 to 1995 was used. Of these, 21,349 were CABG patients, 3,275 were valve replacement patients and 1,351 were CABG plus valve patients.
Study design
For both studies, the analyses seem to have been based on retrospective cohort studies (although it was not clearly expressed), which were collected from the Emory University Hospitals database. The baseline variables were recorded. The outcome data were recorded at one year and every 5 years' post-procedure, and during all cardiac rehospitalisations. The average length of follow-up was not reported.
Analysis of effectiveness
For all analyses, it appears that all of the patients enrolled in the study were taken into account when estimating the effectiveness. The primary study outcomes were mortality rates, occurrence of AF, length of stay in the hospital, and the impact of demographic, clinical, angiographic and surgical characteristics on the probability of developing AF. The development of AF was estimated using a multivariate logistic regression analysis. The c-index values of the discriminatory power of the regression models were reported. Finally, the hazard ratios of death from AF for the three samples were calculated.
Effectiveness results
The mortality rate ranged from 2.6% in the CABG group to 11.7% in the CABG plus valve group.
AF occurred in 17.7% of the patients in the CABG group, in 24.6% of those in the valve group, and in 33.8% of those in the CABG plus valve group.
AF was associated with an increase in post-procedural length of stay of 3.4 days in the CABG group, 3.3 days in the valve group, and 6.4 days in the CABG plus valve group.
Multivariate predictors of the recurrence of postoperative AF for the CABG sample were age (odds ratio, OR, 1.84, 95% confidence interval, CI: 1.73 -1.95), gender (OR 0.85, 95% CI: 0.75 -0.97), bypass time (OR 1.03, 95% CI: 1.02 -1.05) and prior myocardial infarction (OR 0.87, 95% CI: 0.77 -0.98).
The predictors for the valve sample were age (OR 1.44, 95% CI: 1.30 -1.60), chronic obstructive pulmonary disease (OR 1.60, 95% CI: 1.07 -2.41), and smoker condition (former smoker versus never smoked, OR 0.91, 95% CI: 0.68 -1.24; current smoker versus never smoked, OR 0.59, 95% CI: 0.37 -0.94).
The predictors for the valve sample were age (OR 1.53, 95% CI: 1.29 -1.83) and renal insufficiency (OR 1.97, 95% CI: 1.26 -3.08) in the CABG plus valve group.
The c-index was 0.68 for the CABG model, 0.67 for the valve replacement model, and 0.65 for the CABG plus valve model.
For CABG patients who developed postoperative AF, the hazard ratio for death was 1.19 (95% CI: 1.09 -1.30). There was no significant hazard of death from postoperative AF for the other two groups. 
Clinical conclusions
The effectiveness analysis showed the predictors of post-procedural AF and other outcome data. These were used in the decision model in the cost-effectiveness study.
Modelling
A multivariate logistic regression model was used to examine the effect of several demographic, clinical, angiographic and surgical characteristics on the development of AF. The c-index was also developed to define the ability of the regression model to discriminate among patients with respect to their outcomes. The model was validated internally using a bootstrap analysis (150 bootstrap samples). Finally, a decision analytic model was used to determine the costeffectiveness of amiodarone in comparison with no amiodarone.
Methods used to derive estimates of effectiveness
The authors made an assumption relating to the efficacy of IV amiodarone, which was derived from a published trial.
Estimates of effectiveness and key assumptions
The efficacy of IV amiodarone was assumed to have been 26%.
The long-term cost-utility model made two other model assumptions for the base-case. First, an event had no effect on utility in the first year. Second, the effect of an event averted on long-term mortality was 100%.
Measure of benefits used in the economic analysis
In the cost-effectiveness study, the proportion of cases averted (based on the AF rate) was used as the benefit measure in the economic analysis. It was derived from modelling, although the details of this were not reported. In the costutility analysis, the benefit measure was quality-adjusted life-years (QALYs). Data on survival were derived from the effectiveness study involving 25,975 patients and using the Cox regression proportional hazards model, while the source of utility data was not reported. In the cost-utility analysis, the life-years were discounted at a rate of 3%.
Direct costs
The economic evaluation incorporated hospital and professional costs. The cost/resource boundary adopted in the study was that of the hospital for hospital costs and that of the payer for professional charges. The costs were estimated from the UB-92 formulation of hospital bills for hospital charges and from Current Procedural Terminology codes for professional charges. The longer-term costs were also considered for the long-term cost-utility model. Charges were converted into costs using a departmental cost-to-charge ratio. The costs were discounted at a rate of 3% in the costutility analysis only, as a long-term perspective was adopted. The unit costs were not reported separately from the quantities of resources and a breakdown of the costs was not given. No price year was reported.
Sensitivity analysis
Sensitivity analyses were conducted to assess the influence of variations in the cost of therapy, efficacy of therapy and the cut-off probability of AF for initiating therapy on the estimated cost-effectiveness ratios. Two-way sensitivity analyses were conducted. The base-case assumptions on the effect on utility in the first year and the effect of an event averted on long-term mortality were varied.
Estimated benefits used in the economic analysis
The treatment threshold (the predicted risk of AF above which amiodarone therapy would be initiated) was varied from 0 to 100. This resulted in an AF rate ranging from 13.1 to 17.7% in the CABG group, from 18.2 to 24.6% in the valve group, and from 25 to 33.8% in the CABG plus valve group.
In the cost-utility analysis, the mean discounted (3%) life-years over the 5-year follow-up was 4.18 years for patients without AF and 3.92 years for patients with AF.
The number of QALYs gained was not reported.
Cost results
As the treatment threshold varied from 0 to 100, the mean costs of the treatment ranged from $24,443 to $23,296 in the CABG group, from $32,121 to $31,330 in the valve group, and from $40,784 to $40,384 in the CABG plus valve group.
Synthesis of costs and benefits
An incremental analysis was conducted to combine both the benefits (QALYs and the proportion of AF cases averted) and costs.
In the cost-effectiveness analysis, as the treatment threshold was varied from 0 to 100, the incremental cost per AF event averted for a strategy of treating patients at one cut-off level versus the next highest cut-off level ranged from $55,854 to $10,938 in the CABG group, from $43,011 to $4,219 in the valve group, and from $39,698 to $69 in the CABG plus valve group.
In the cost-utility analysis for CABG patients, in the base-case, the cost per QALY gained ranged from $824,786 at the 0 -10% treatment threshold to $174,089 at the 45 -50% treatment threshold.
The sensitivity analysis for the cost-utility analysis of CABG patients showed that, if the utility of a patient for the first year was reduced by 20% due to an AF event, the cost per QALY gained would be significantly reduced with amiodarone use at all treatment thresholds. The cost per QALY gained fell below $50,000 at the 45 -50% treatment threshold.
The effect of an event averted on long-term mortality had little effect on the cost per QALY gained in comparison with the effect on utility. Still, assuming a 20% drop in utility from an AF event, if the effect on long-term mortality from an event averted were reduced from 100 to 0%, the cost per QALY gained would only increase from $47,553 to $65,423 at the 45 -50% treatment threshold.
